IL6 and type 1 diabetes mellitus: To conclude, heavily reducing pre- and post-exercise rapid-acting insulin dose does not induce hyperketonaemia, excessively raise inflammatory cytokines TNF-α or IL-6, or cause other metabolic or hormonal disturbances in type 1 diabetes patients treated with insulin glargine and fast-acting insulin aspart or lispro.